AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
PMV Pharma reports 34% ORR in 103 evaluable patients across all cohorts.
ByAinvest
Friday, Oct 24, 2025 11:45 am ET1min read
PMV Pharmaceuticals presented data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, showing a 34% overall response rate among 103 evaluable patients across eight tumor types. The median duration of response was 7.6 months. A 46% response rate was observed in the ovarian cancer cohort, with a median duration of response of 8.0 months. A New Drug Application submission for platinum-resistant/refractory ovarian cancer is planned for the first quarter of 2027.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet